The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting.

For reasons beyond our control we have the right to immediately alter or cancel the conference or any arrangements, timetable, plans or items relating directly or indirectly to the conference. The participants shall not be entitled to any compensation for damages that result from such alteration or cancellation. It is highly recommended that all participants carry the proper individual travel and health insurance.

The British Association for Psychopharmacology is registered in England as a Private Limited Company No 5866899. Registered Charity No 277825. Registered Office: 36 Cambridge Place, Hills Road, Cambridge CB2 1NS.
Hall H – Posters, Exhibition, Refreshments, Lunches
BAP OFFICERS AND COUNCIL MEMBERS

Until the 2012 Annual General Meeting (23 July, Hall D)

OFFICERS

President: Nicol Ferrier (Newcastle)
President-elect: Barbara Sahakian (Cambridge)
Past-President: Gavin Reynolds (Sheffield)
Honorary Treasurer: Catherine Harmer (Oxford)
Honorary General Secretary: Peter Haddad (Manchester)
Meetings Secretary: Jo Neill (Bradford)
Secretary for Clinical External Affairs: Naomi Fineberg (Welwyn Garden City)
Secretary for Non-Clinical External Affairs: Paula Moran (Nottingham)

COUNCIL

Carmine Pariante (London) Marcus Munafo (Bristol)
Anne Jackson (Brighton) Liz Tunbridge (Oxford)
Val Curran (London) Mitul Mehta (London)
Steve Bazire (Norwich) Hugh Marston (Edinburgh)

Co-opted Members:
Jeffrey Nye (New Jersey)
Mark Tricklebank (Windlesham)

Ex-Officio Council Members:
BAP Editor: David Nutt (London)
RCPsych PSIG Chair: Allan Young (London)
BAP Director of Education: Hamish McAllister-Williams (Newcastle)

BAP PAST PRESIDENTS

Max Hamilton Malcolm Lader David Nutt
Alec Coppen Brian Leonard Charles Marsden
Philip Bradley Stuart Montgomery Guy Goodwin
Merton Sandler Barry Everitt Clare Stanford
Eugene Paykel Bill Deakin Thomas Barnes
Susan Iversen Trevor Robbins Gavin Reynolds

HONORARY MEMBERS

Professor George Beaumont Dr Paul Leber
Dr Alec Coppen Professor Brian Leonard
Dr Timothy Corn Professor Eugene Paykel
Professor Susan Iversen Professor Merton Sandler
Professor Malcolm Lader Professor Hannah Steinberg

GOVERNANCE PANEL

Professor Charles Marsden (Chair) Dr Clare Stanford Professor Guy Goodwin
GENERAL INFORMATION

All activities take place at Harrogate International Centre (HIC) unless stated otherwise

Abstract Supplement: The numbers next to the presentations and posters in this Programme are the abstract numbers as printed in the Supplement

BAP Annual General Meeting: Hall D on Monday at 17:30

Certificates of Attendance: Will be emailed to attendees after the Conference, upon request

Editorial Board Meeting (JoP): Meeting Room 1 on Tuesday at 12:45

Editorial Board Meeting (TA): Meeting Room 1 on Tuesday at 13:45

Exhibition: Pharmaceutical companies/publishers/technical equipment/services in Hall H for the duration of the conference

Guest Lecture: Nora Volkow, Hall D, Monday at 14:30

Internet Café: Available in the foyer of Hall H

Luggage storage: A cloakroom will be available at Queen’s Suite for storing luggage on Wednesday morning

Lunch: Included in the registration fee, in Hall H on Monday and Tuesday

Mental Health Session: The best treatment for treatment-resistant patients with psychiatric disorders and possibilities for developing clinical research Hall D, Monday at 15:30

Name Badges: Must be worn at all times at HIC. If you lose your badge please collect another from the BAP desk. We recycle name badge holders – please leave yours at the BAP desk before departure

Photography and Recording: Strictly prohibited during all sessions

Post-doctoral Symposium: Neurodevelopmental models of psychiatric disease: back to the future Queen’s Suite 1, Tuesday at 11:45

Posters: Two sessions in Hall H: Session 1 11:30-13:15 on Monday Session 2 14:00-15:15 on Tuesday Posters may be mounted from 08:30 on Monday and, wherever possible, should remain in place until the end of the meeting on Wednesday Poster presenters should stand by their poster for one hour during their designated session
Pre-Clinical Certificate Module: Queen’s Suite 1, Sunday 13:30-17:30

Prize-giving: 2012 Prizes and Awards will be presented by the President at the Conference Dinner on Tuesday

Psychopharmacology Award Prize Winners: Short Oral presentations in Queen’s Suite 1 on Tuesday, 16:15-17:00

Reception and Conference Dinner: The Majestic Hotel, Tuesday at 19:00 (for those who have purchased a ticket)

Refreshments: Included in the registration fee, available in Hall H at designated breaks

Registration and Information: BAP desk outside the Queen’s Suite at the following times:

- Sunday 11:00-18:30
- Monday 08:30-17:30
- Tuesday 08:30-17:00
- Wednesday 09:00-12:30

Satellite Symposia: Monday: Lundbeck, Queen’s Suite 1 at 13:15-14:15
- Monday: Roche, Queen’s Suite 2 at 13:15-14:15
- Monday: Lilly, The Ballroom, Majestic Hotel at 18:30-21:00
- Monday: Janssen, The Reading Room, Majestic Hotel at 18:30-21:15

Short Oral Sessions: Tuesday 15:15-16:15 in Queen’s Suites 1 & 2, and Hall D

Speaker Preview Room: In the conference link

Special Session: Reading and Drawing Rooms, Majestic Hotel at 17:00-19:30

Statistics Clinic: In Hall H on Monday

Symposia: 1, 4, 7 in Hall D; 2, 5, 8 in Queen’s Suite 1; 3, 6, 9 in Queen’s Suite 2

Welcome Drinks Reception: Sunday at 19:30 in the Billiard Room at the Majestic Hotel (President’s Welcome at 20:00)

Wi-Fi cards: Available at the HIC information desk
2012 LIFETIME ACHIEVEMENT AWARD

The BAP Council is delighted to announce that the 2012 Award will be presented to

Professor Barry Everritt FRS FMedSci.

Barry has worked in the area of Psychopharmacology for more than 40 years and continues his research as Professor of Behavioural Neuroscience, University of Cambridge. He is also Master of Downing College, Cambridge. He has published 377 papers and his h-index is 94. He was elected Fellow of the Royal Society in 2007 and Fellow of the Academy of Medical Sciences in 2008.

Barry served as President of the European Brain and Behaviour Society (1998-2000) and of the European Behavioural Pharmacology Society (2003-2005). He was Elected Foreign Corresponding Member of the American College of Neuropsychopharmacology in 1999. He has been an ISI “Highly Cited” Researcher since 2004 and he is frequently invited to give plenary lectures at major international conferences. He has acted as advisor on Psychopharmacology to several counties including Spain, Finland, the Netherlands, Sweden and France. He was recently awarded the American Psychological Association’s Award for Distinguished Scientific Contributions (2011) and the 2012 FENS EJN Award (given in recognition of “outstanding scientific work in all areas of neuroscience”)

Barry’s research has contributed immensely to our understanding of the neural mechanisms of reward mechanisms, drug-seeking behavior and relapse. His work has had a tremendous impact on the field, for example he is among the world’s 100 most highly cited neuroscientists. He has been and is in receipt of programme grant funding from major UK competitive grant awarding bodies.


Barry is a longstanding member of BAP and member of Council (1984-1996). As Secretary in 1986 he recruited Susan Chandler and he was BAP President 1992-1994. Barry has made major contributions to the organisation of BAP conferences (including hosting joint meetings) and has been a member of the Editorial Board of Journal of Psychopharmacology since its inception.

We are delighted that Barry will accept the 2012 Lifetime Achievement Award at the conference dinner in Harrogate on Tuesday 24 July.
2012 PRIZE WINNERS

BAP PSYCHOPHARMACOLOGY AWARDS
To reward those working in non-clinical and clinical psychopharmacology
Oral presentations will be on Tuesday 24 July at 16:15 in Queen’s Suite 1
The Review Panel, comprising BAP Council Members, had an extremely difficult task this year, reviewing applications and nominations from a number of high-quality candidates
After extensive discussions, it was agreed to present the Awards to the following BAP Members:
Karen Ersche (University of Cambridge)
Presentation title: Lifting the veil on addiction vulnerability
Marcus Munafo (University of Bristol)
Presentation title: Power, precision and phenotype in genetic association studies
Cynthia Fu (Institute of Psychiatry, London)
Presentation title: Developing neuroimaging-based biomarkers for diagnosis and prognosis in depression

ROBERT KERWIN INTERNATIONAL CONFERENCE BURSARIES
Professor Rob Kerwin was instrumental in advising, supporting and acting as mentor for numerous people early in their careers in psychopharmacology. To commemorate this, the Council of BAP introduced annual bursaries in 2008, to be awarded in his name.
The 2012 Robert Kerwin International Conference Bursaries were awarded to Michael Browning (Oxford), to attend the Anxiety Disorders Association of America Annual Conference, and Christoph Anacker (London), to attend the Society of Biological Psychiatry Annual Conference in May 2013.

BAP/CAMBRIDGE COGNITION AWARD
The BAP and Cambridge Cognition are strongly committed to promoting and encouraging research in the area of Psychopharmacology that could directly, and in the near term, translate to patient care.
This Award, new for 2012, particularly rewards translational approaches in Psychopharmacology.
The winner of the 2012 BAP/Cambridge Cognition Prize is Valeria Mondelli (London). Valeria will present Poster MF08 on Monday, on the work which formed part of her application “The effects of stress and its biological mediators on hippocampal volume in first-episode psychosis”.

HANNAH STEINBERG BURSARY
Thanks to the generosity of Professor Hannah Steinberg and The Wolfson Foundation we are pleased to award a special bursary each year for attendance at the Summer Meeting. The recipient this year is Jason Thomas (Birmingham). Jason will present Poster TG02 on Tuesday “Effect of meta-chlorophenylpiperazine (mCPP) on emotional processing and mood in healthy volunteers”.

POSTER PRIZES AND UNDERGRADUATE AWARDS
Decisions will be made during the conference and winners announced at the Conference Dinner on Tuesday.
BURSARIES
The Council of BAP is committed to supporting young scientists with various initiatives. For the 2012 Summer Meeting we have awarded almost 70 bursaries to assist Training Members, Post-Docs and Undergraduates to attend the conference.

We are extremely grateful to the Gatsby Charitable Foundation for their generous contribution towards the 2012 bursary fund.

ACKNOWLEDGEMENTS
BAP acknowledges contributions from the following companies who will take part in the 2012 Summer Meeting by supporting a Special Session, Satellite Symposia and exhibition stands:

- Janssen
- Lilly
- Lundbeck
- Pfizer
- Roche
- Servier
- AOP Orphan Pharmaceuticals AG
- Cambridge Cognition
- Shire
- Tracksys

POSTER PRESENTATIONS
- All posters must be exhibited in LANDSCAPE format.
- Posters may be mounted from 08:30 on MONDAY 23 JULY
- All posters should be mounted by 11:30 on MONDAY and should remain in position until the end of the meeting on Wednesday wherever possible.
- All posters must be mounted with the Velcro provided
- Conference staff will remove any poster carrying a different title to that which is on the accepted abstract
- Presenters should stand by their poster for one hour during their designated session

ORAL PRESENTATIONS
The time allocated to each oral presentation is to allow questions from, and discussion with, the audience. This interaction is an important component of BAP Summer Meetings, reflecting our philosophy of promoting discussion and debate. Keeping to time is particularly important as attendees often wish to hear talks in different sessions. Session chairs are asked to strictly enforce the time allocated to each presenter.
FULL PROGRAMME

PLEASE NOTE: All activities take place at Harrogate International Centre (HIC) unless stated otherwise

SUNDAY 22 JULY

13:30 Preclinical Certificate Module 5
Queen’s Suite 1
*Functional and Advanced Techniques – The development of pharmacological agents*

13:30 Registration and refreshments

13:40 Introduction
Hugh Marston (TPP, Edinburgh)

13:45 Pre-clinical drug development: stages, techniques and complexities
Hugh Marston (TPP, Edinburgh)
To set the scene for the afternoon; to detail phases of drug development and some of the pre-clinical methods used to progress a compound

14:20 Challenges in the uses of human imaging in drug development
Mitul Mehta (King’s College, London)
The uses and utility of PET and fMRI in Phase 1 drug studies

15:30 Refreshments

15:40 Biomarkers of antidepressant action
Catherine Harmer (Oxford University)
Discussion of the need for biomarkers for antidepressant drug treatments and the progress of recent projects with industry

16:15 Roundtable Discussion
Each speaker provides one topical question to be discussed (one topic per group). The group debate how to address it.

17:00 Close of meeting

The aim of the module is to present basic concepts as well as examples of cutting edge research in processes and techniques used for the industrial development of pharmacological agents and pre-clinical psychopharmacological research.

The first speaker will set the scene and explore pre-clinical animal models used to progress a new compound. This will be followed a careful local at the use of PET and fMRI in Phase I studies. Finally, the development of biomarker for use in studying potential antidepressants will be explored. The speakers will cover drug development from an industry perspective but also methodological and scientific issues relevant to the academic audience. The aim also being to illustrate the variety available, and the need to make a balance that needs to be made, between animal and human pre-clinical approaches. Following the three talks there will be a roundtable session allowing course participants to raise issues in this area with the speakers as well as respond to three discussion points set in advance by the speakers.
**BAP Special Session supported by Servier**
Reading and Drawing Rooms, Majestic Hotel

**Neurogenesis, resilience and antidepressants**
Chaired by David Baldwin (Univ of Southampton)

This session will provide an opportunity to hear and discuss new developments in understanding of the effects of antidepressant drugs on neurogenesis, and of the role of antidepressant treatment in enhancing resilience to adversity. Carmine Pariante and Hamish McAllister-Williams are internationally regarded researchers in the area of affective disorders, and play significant roles within the BAP.

17:00 Afternoon tea
17:30 **Introduction to the Special Session**
David Baldwin
17:40 **Antidepressants and neurogenesis: back to the future**
Carmine Pariante (Inst of Psychiatry)
18:10 **Questions and answer session**
18:20 **Stress, vulnerability and resilience – the role of antidepressants**
Hamish McAllister-Williams (Newcastle Univ)
18:50 **Questions and answer session**
19:00 End of Special Session

19:30 **Welcome Drinks and Canapés in the Billiard Room, Bar and Terrace at the Majestic Hotel**
(The BAP President will give a short welcome address at 20:00)

21:30 Disco in the Billiard Room at the Majestic Hotel
**MONDAY 23 JULY**

08:30  BAP desk opens in the Foyer of the Queen’s Suite

09:00  **Symposia 1, 2 and 3 in parallel**  
Hall D, Queen’s Suite 1, Queen’s Suite 2

09:00  **Symposium 1 – Hall D**

**Drugs as tools in neuropsychiatry: Ketamine**  
Chair: Barbara Sahakian (Cambridge)

09:00  **The translational neuropharmacology of ketamine**  
Bill Deakin (Manchester)

09:30  **Ketamine in healthy volunteers as a model of schizophrenia**  
Paul Fletcher (Cambridge)

10:00  Refreshments in Hall H

10:30  **Ketamine and the potential role for rapid acting antidepressants**  
John Krystal (New Haven)

11:30  **Animal models of neuropsychiatric disorders: Ketamine and related drugs**  
Thomas Steckler (Belgium)

09:00  **Symposium 2 – Queen’s Suite 1**

**New tricks for old drugs: Opiates, addiction and beyond**  
Chairs: Sarah Bailey (Bath), Hilary Little (London)

09:00  **Enhancing the pharmacology of buprenorphine as a treatment for drug addiction**  
Chris Bailey (Bath)

09:30  **Opioid antagonists for alcohol dependence**  
Karl Mann (Heidelberg)

10:00  Refreshments in Hall H

10:30  **Role of opioid receptors in stress and depression**  
Sarah Bailey (Bath)

11:00  **Risk of death during and after opiate substitution therapy:**  
Evidence from European and Australian cohorts  
Matthew Hickman (Bristol)
Symposium 3 – Queen’s Suite 2

Advances in understanding brain corticosteroid responses to stress: relevance to depression
Chairs: Carmine Pariante (London), Andrea Malizia (Bristol)

09:00  Ultradian patterns of corticosterone release and their influence on healthy stress responses: A translational approach
Stafford Lightman (Bristol)

09:30  Rapid and slow effects of corticosteroids in the rodent and human brain: Relevance for cognitive performance
Marian Joels (Utrecht)

10:00  Refreshments in Hall H

10:30  Are corticosteroids essential for antidepressant response? Evidence from preclinical studies
Joe Herbert (Cambridge)

11:00  Upstream: Genetic polymorphisms regulating glucocorticoid-stimulated gene expression – relevance for the pathophysiology and treatment of depression
Elisabeth Binder (Munich)

11:30  Poster Session 1 and lunch in Hall H

Anxiety 1 / Affective Disorders 1 / Brain Imaging / Cognition 1 / Educational Psychopharmacology / Schizophrenia 1 / Substances of Abuse 1
Presenters should stand by their poster between 11:30-12:30
MONDAY GROUP A

ANXIETY 1

Performance in an instrumental successive negative contrast task by Wistar rats with an anxiety-like phenotype  
**Mitchell EN**, Marston HM, Nutt DJ, Lodge D, Robinson ESJ  
*This will also be presented orally on Tuesday afternoon*

From rodents to patients: prefrontal cognitive and hypothalamic-pituitary-adrenal (HPA) axis function following trauma exposure  
**Lapiz-Bluhm MD**

Effect of tryptophan supplementation on the cortisol response to social stress is modulated by 5-HTTLPR genotype  
**Cerit H**, Van der Does AJW, Jans LAW

Using 7.5% CO2 challenge to evaluate novel psychological treatments for anxiety  
*This will also be presented orally by Morris JL on Tuesday afternoon*

WITHDRAWN

An investigation of attention process in chronic fatigue syndrome: health-threat related attentional bias and the role of attentional control  

Probiotics and the brain: Effects on anxiety and reversal learning  
**O’Hagan CM**, Lilburn A, Good MA  
*This will also be presented orally on Tuesday afternoon*
MONDAY GROUP B
AFFECTIVE DISORDERS 1

Antidepressant effects of novel kappa-opioid receptor antagonists in the forced swim test
**Bailey SJ**, Casal-Dominguez JJ, Husbands, SM

Wistar Kyoto rats have a “depressive-like” phenotype accompanied by functional alterations of brain microtubules and changes in microtubular proteins in the hippocampus
**Cottin J**, Leandri J, Parésys L, Baulieu EE, Bianchi M

The effects of chronic fluoxetine in the rodent affective tones discrimination task
**Anderson MH**, Robinson ESJ

The sex-differentiated behavioral response in the forced swim stress following sertraline treatment
**Kokras N**, Dalla C, Kafetzopoulos V, Mikail HG, Papadopoulou-Daifoti Z

Short-term antidepressant administration modulates cardiovascular response during emotion regulation in subjects at risk for psychopathology
**Di Simplicio M**, Western D, Hanson B, Taggart P, Harmer CJ

Familial depression: finding biomarkers of vulnerability
**McCabe C**, Woffindale C, Harmer CJ, Cowen, PJ

Does maternal history of childhood abuse affect mental health during pregnancy?
**Fantini E**, Conroy S, Pawlby SJ, Osborne SA, Pariante CM

Verbal memory in postpartum psychosis
**Hazelgrove KM**, Pauls AM, Mehta MA, Pawlby S, Ciufolini S, Pariante CM, Morgan K, Dazzan P

Mother-infant interaction in MBU patients: Before and after treatment
**Kenny MA**, Conroy S, Pariante C, Seneviratne T, Pawlby S

Th1/Th17 and Treg/Teffector imbalance in depressed COPD patients

Candidate genes expression profile associated with antidepressants response: differentiating between baseline “predictors” and longitudinal targets

The role of immune genes in the association between depression and inflammation: A review of clinical studies
**Bufalino C**, Hepgul N, Aguglia E, Pariante CM

The effects of psychosocial stress on clinical outcomes during IFN-α treatment
Effect of Interferon-α on cortical glutamate and depressive symptomatology in patients with hepatitis C: a proton MRS study


T3/T4 augmentation of treatment resistant depression

Adewusi ODT, Sule A, Nandhra H

Sleep is similar in patients with treatment-resistant depression at different stages: influence of different antidepressants

Durant CF, Malizia AL, Glue P, Nutt DJ, Wilson SJ

Comparison of depression outcomes in patients with treatment resistant depression undergoing deep brain stimulation. Results from the Bristol DBS Depression (BDBS-D) pilot study

Harrison L, Malizia AL, Durant C, Wilson S, Rich A, Nutt D, Patel NK

Beneficial effects of DBS for severe and chronic treatment resistant depression are not achieved by stimulating Brodmann’s area 25 or the nucleus accumbens. Results from the Bristol DBS for Depression (BDBS-D) pilot study


Comparison of emotional processing in patients with severe treatment-resistant depression (TRD) and healthy matched controls: Ekman faces and Emotional Stroop

Diaper A, Durant C, Rich AS, Patel NK, Malizia AL

Response to hydrocortisone infusions in patients with treatment resistant major depressive disorder: the TUDOR study


MONDAY GROUP C

BRAIN IMAGING

Exquisite delineation of hippocampi, retrocommissural formation and indeusium griseum by hydrocortisone infusion using arterial spin labelling MRI in man

McGonigle J, Holmes R, Tyacke RJ, Zelaya F, Lightman S, Nutt DJ, Williams SCR, Malizia AL

The contribution of sub-cellular binding to dopamine and opioid receptor PET ligands

Quelch DR, Parker CA, Nutt DJ, Tyacke RJ

The neural mechanisms underpinning decision tree ‘pruning’

Lally N, Huys QJM, Eshel N, Dayan P, Roiser JP

Habenula responses to aversive stimuli in humans: a high-resolution fMRI study


Donepezil modifies the distribution of changes in regional cerebral blood flow induced by scopolamine administration in healthy volunteers
Doyle OM, Zelaya FO, O’Daly OG, Williams SCR, Mehta MA

Lateralised cortical response to pharmacological stimulation of glucocorticoid and mineralocorticoid receptors in man
Tyacke RJ, McGonigle J, Holmes R, Zelaya F, Lightman S, Nutt DJ, Williams SCR, Malizia AL

Abnormalities in anatomical cortico-subcortical connectivity associated with chronic ketamine use
Roberts RE, Morgan CJA, Curran HV, Roiser J

Brain glutamate levels in chronic ketamine users – relevance to schizophrenia
Stone JM, Pepper F, Curran V, Morgan C, Howes O

Default mode network in the effects of Δ9-tetrahydrocannabinol (THC) on human executive function
Bossong MG, Jansma JM, Van Hell HH, Jager G, Kahn RS, Ramsey NF

Altered default mode network connectivity after psilocybin

Nicotine enhances prospective memory performance in APOE E4 carriers: an fMRI study
Evans SL, Gray M, Dowell NG, King SL, Tabet N, Tofts PS, Rusted JM

MONDAY GROUP D
COGNITION 1

A dimeric inhibitor of the NMDA-R/PSD-95/nNOS interaction reduces inflammatory pain without disrupting motor or cognitive performance: comparison with the NMDA receptor antagonist MK-801
Andreasen JT, Bach A, Gynther M, Mogensen J, Strømgaaard K, Pickering DS

Modifications to the 5-choice serial reaction time task reduces impairments in attention and impulse control associated with NMDA receptor antagonism
Benn A, Robinson E

Preclinical modelling of attentional deficits and impulsivity of relevance to ADHD: pharmacological evaluation studies using the 5-CSRTT and implications for therapy of adult ADHD
Tomlinson A, Marshall KM, Neill JC
The effects of the L-Type Cav channel blocker, nifedipine, on behaviour of wildtype and NK1 receptor or ‘knockout’ mice differ in the 5-choice serial reaction time test


A proof-of-concept investigation of genotype-dependent noradrenergic effects on attention

**Chan KFD**, Gibbs AA, Somal S

A proof-of-concept investigation of genotype-dependent noradrenergic effects on memory

**Somal SK**, Gibbs AA, Chan KFD

A pharmacological evaluation of efficacy to reverse delay dependent episodic memory deficits in the object place context task in female rats

**Fawcett H**, Grayson B, Neill JC

The influence of anxiety and depressive symptoms on the access of emotional stimuli to awareness – a study using Continuous Flash Suppression (CFS)

**Capitão LP**, Underdown S, Vile S, Yang E, Harmer CJ, Murphy SE

Opioid induced changes in memory functioning: A randomised, controlled, cross-over study in palliative care patients

**Kamboj SK**, Conroy L, Carrol E, Tookman A, Jones L, Curran HV

### MONDAY GROUP E

**EDUCATIONAL PSYCHOPHARMACOLOGY**

Quality of case reports of adverse drug reactions with psychotropic drugs

**Talat B**, Mayers A, Baldwin DS

‘As required’ drug prescribing in acute inpatient psychiatry: a retrospective study – preliminary findings

**Preeti G**, Rasquinha N, Dratcu L

A retrospective study of clozapine in emotionally unstable personality disorder

**Picchioni M**, Frogley C, Anagnostakis K, Mitchell S, Mason F, Dickens G

Attitudes of undergraduate students towards recreational drug use and mental illness

**Loxton K**, Deslandes RE, Deslandes PN

How much do doctors know about alcohol consumption and alcohol use disorders?

**Brandish EK**, Sheron N, Baldwin DS, Sinclair JMA
MONDAY GROUP F
SCHIZOPHRENIA 1

Glutamate microsensors reveal altered glutamate signalling in hippocampal slices from a rat neurodevelopmental model of schizophrenia
King MV, Fone KCF

Sub-chronic PCP alters GABAA transporter and vesicular glutamate transporter gene transcription in the frontal cortex of female Lister-Hooded rats
Glasper JE, Harte MK, Atack J, Neill JC

Deficits of the neuronal marker N-Acetylaspartate in the frontal cortex and ventral hippocampus following sub-chronic phencyclidine treatment in the female rat

S(+)-ketamine as a model for psychosis
Kleinoog D, Uit den Boogaard A, Klaassen E, Van Gerven J

Risperidone reverses some behavioural deficits caused by combined post-natal phencyclidine treatment and isolation rearing post-weaning in rats
Gaskin PLR, Fone, KCF, Alexander, SPH

Effects of chronic antipsychotic drug treatment on cell numbers in the frontal cortex of male rats
Vernon AC, Chege W, Natesan S, Modo M, Cooper JD, Williams SCR, Kapur S

Different molecular pathways mediating metabolic abnormalities of first- and second-generation antipsychotics

The effects of stress and its biological mediators on hippocampal volume in first-episode psychosis
Mondelli V

Winner of the BAP/Cambridge Cognition Award 2012

The effects of haloperidol and aripiprazole on reward task performance in healthy volunteers

The 5-HT1A promoter polymorphism and antipsychotic treatment response - pharmacogenetic association with the five syndrome dimensions in PANSS
Tang H, Arranz B, San L, Reynolds GP

Characteristics of patients prescribed quetiapine Instant Release (IR) and Extended Release (XL) formulations in a primary care database (GPRD)
Rigney U, Emmas C, Blak BT, Lichfield J, Wootton P
Psychiatrists’ perspectives regarding antipsychotics: dose choice and plasma level therapeutic drug monitoring
Best-Shaw, Nagar J, David AS, Rose D, Patel MX

Community Treatment Orders and antipsychotic formulations: naturalistic outcomes
Patel MX, Matonhodze J, Baig MK, Taylor D, Szmukler G, David AS

MONDAY GROUP G
SUBSTANCES OF ABUSE 1

Harnessing drug-user experiences to evaluate the verisimilitude of pharmacological models of psychiatric illness
Brugger S, Carhart-Harris R, Nutt D, Stone JM

Future thinking abilities of illicit drug users
Mercuri K, Terrett G, Rendell PG

In vivo brain dopamine synthesis capacity and cannabis related psychotic symptoms: an [18F]-DOPA Positron Emission Tomography study in cannabis users
Bloomfield MAP, Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD
This will also be presented orally on Tuesday afternoon

Executive function deficits in abstinent cannabis users: The effect of the age of onset
Reynolds J, Mchale S, Barker L, Reidy L, Dalton C
This will also be presented orally on Tuesday afternoon

Frontal brain volumes in early adolescence differentially predict the development of alcohol-related problems and cannabis use at age 16: a 4-year longitudinal and prospective cohort study
Lubman DI, Cheetham A, Whittle S, Simmons J, Yucel M, Allen NB
This will also be presented orally on Tuesday afternoon

Automatic alcohol cognitions in heavy drinkers: Strong appetitive tendencies, weak avoidance tendencies, or both?
Field M, Dickson J, Gullo M

Relationship of cytokine concentrations with the severity of alcohol hangover symptoms
van Seyen M, Cheung CW, Slot KA, Penning R, Olivier B, Verster JC

In vivo imaging of cerebral dopamine D3 receptors in alcoholism

Subjective response to alcohol in harmful and hazardous drinkers: an acceptability and feasibility pilot study
Hasnaoui SK, Carrick OG, Koshnow Z, Brandish E, Garner MJ, Sinclair JMA
13:15   Satellite Symposium hosted by Lundbeck – Queen’s Suite 1

Optimising the treatment of bipolar disorder
Chaired by Hamish McAllister-Williams (Newcastle)

13:15   Chair’s opening comments
Hamish McAllister-Williams

13:20   From bench to clinic: Translating the receptor profile into possible clinical effects
David Nutt (London)

13:45   From bench to clinic: Translating the receptor profile into tolerability effects
Gavin Reynolds (Sheffield)

14:10   Chair’s concluding comments

14:15   Close

13:15   Satellite Symposium hosted by Roche – Queen’s Suite 2

Understanding Negative Symptoms in Schizophrenia
Chaired by Bill Deakin (Manchester)

13:15   Introduction
Bill Deakin

13:25   The Clinical Impact of Negative Symptoms
Thomas Barnes  (London)

13:45   Glutamate and the development of psychosis
James Stone (London)

14:05   Questions and answer session

14:15   Close
Drugs in the Brain: transforming reward into addiction

Nora D Volkow
Director, National Institute on Drug Abuse

Chemicals that activate the reward system are reinforcing to humans (but also to a wide variety of animals from reptiles into humans) including humans. Their supraphysiological activation of the brain reward systems (including dopaminergic activation via D1 and D2 receptors in the nucleus accumbens) is believed to be the starting point for the neurobiological changes that launch the addiction trajectory (including dysregulation of glutamatergic signaling through NMDA and AMPA receptors in limbic regions and frontal cortex). Research on addiction has started to uncover the sequence of events and long-lasting sequelae that can result from the persistent abuse of addictive substances (including nicotine and alcohol). These studies have shown how repeated drug use can target key molecules (both common and specific for various drugs types) and brain circuits, and eventually disrupt the higher order processes that underlie emotions, cognition and behavior and that enable and individual to exert self-control. Specifically pre-clinical and clinical brain imaging studies have shown that addiction is characterized by an expanding cycle of dysfunction in the brain. The impairment appears to start in the evolutionarily more primitive areas that process reward, but then moves on to other brain regions responsible for more complex cognitive functions. Thus, in addition to reward, addicted individuals can experience severe disruptions in learning (memory, conditioning, habituation), executive (impulse inhibition, decision making, delayed gratification, judgement), cognitive awareness (interoception) and even emotional (mood and stress reactivity) functions. The combined, cumulative impact of addiction on all these circuits results in addicted individuals making poor choices despite awareness of the negative consequences and are unable to delay gratification despite future losses. It also explains why previously rewarding life situations and the threat of judicial punishment cannot stop drug taking and why a medical rather than a criminal approach is more effective in curtailing addiction. In turn this knowledge also informs of strategies for medication development to help buffer the brain dysfunction associated with chronic drug exposures and with addiction.
15:30  **Plenary Mental Health Session - Hall D**

The best treatment for treatment-resistant patients with psychiatric disorders and possibilities for developing clinical research
Chaired by Barbara Sahakian

15:30  **Introduction**
Barbara Sahakian

15:35  The neurochemical and neurobiological basis of treatment-resistance
Stephen Stahl (California)

15:45  **Treatment resistant depression**
Stephen Stahl

16:25  **Treatment resistant bipolar disorder**
Guy Goodwin (Oxford)

16:45  **Medical Research Council initiatives for developing clinical research**
Gavin Malloch (London)

16:55  **Wellcome Trust initiatives for developing clinical research**
Kathryn Adcock (London)

17:05  **Audience questions and discussion**

17:30  **BAP Annual General Meeting – Hall D**

Chaired by Jo Neill, BAP Meetings Secretary

1. Presidential Address  
   Professor Nicol Ferrier

2. Motions for approval:
   2.1 That the Minutes of the 2011 Annual General Meeting be adopted as a correct record  
      Professor Nicol Ferrier
   2.2 That the Editor’s Report be received  
      Professor David Nutt
   2.3 That the Trustees/Directors Annual Report and audited accounts for the period 1 January to 31 December 2011 be received and adopted  
      Professor Catherine Harmer

2.4 That the Honorary General Secretary’s Report be received  
   Dr Peter Haddad

2.5 That the Governance Panel’s Report be received  
   Professor Charles Marsden

3. Discussion chaired by Professor Jo Neill

4. Presidential Medal passed to Professor Barbara Sahakian
18:00  **Satellite Symposium hosted by Janssen**  
*Reading and Drawing Rooms, The Majestic Hotel*

**Continuous treatment in Schizophrenia: Do recent studies change our understanding of its importance in our treatment armamentarium?**  
Chair and Discussant: Professor Sir Robin Murray (London)

18:00  
Hot and cold buffet served in the Reading Room and Drawing Room at the Majestic Hotel

18:45  
Welcome and Introduction

19:00  
**Do antipsychotic drugs shrink the brain and does it matter?**  
Stephen Lawrie (Edinburgh)

19:30  
**What are the treatment options for optimum long-term patient outcomes?**  
Ludger Hargarter (Janssen)

20:00  
**Relapse in schizophrenia: what we know about prediction and prevention**  
Shôn Lewis (Manchester)

20:30  
Discussant and panel Q&A

18:30  **Satellite Symposium hosted by Lilly**  
*The Ballroom, The Majestic Hotel*

**Alzheimer’s Disease – Future Possibilities**  
Chaired by David Nutt (London)

18:30  
Pre-session light refreshments

19:00  
**Start of satellite**  
David Nutt

19:15  
**Can we change the course of Alzheimer’s Disease?**  
Mike Hutton (Lilly)

19:45  
**What will future advances mean to the practising clinician?**  
Roger Bullock (Swindon)

20:15  
Q & A and General discussion

20:45  
Buffet Dinner (Billiard Room, Majestic Hotel)
TUESDAY 24 JULY

08:30  BAP desk opens in the Foyer of the Queen’s Suite

09:00  Symposia 4, 5 and 6 in parallel
        Hall D, Queen’s Suite 1 and Queen’s Suite 2

09:00  Symposium 4 – Hall D

Cognitive impairment in depression: a target for treatment?
Chairs: Philippa Rock (Oxford), Luke Clark (Cambridge)

09:00  Cognitive deficits in mood disorders: an update on imaging and behavioural findings
       Jonathan Roiser (London)

09:30  Rodent models of emotional dysfunction: potential targets for treatment
       Emma Robinson (Bristol)

10:00  Refreshments in Hall H

10:30  Primate models of cognitive dysfunction in depression: Monoaminergic modulation of emotional behaviour and executive function
       Hannah Clarke (Cambridge)

11:00  Pharmacological treatment of cognitive impairment in mood disorders:
       Something old, something new, something borrowed but everything blue
       Zubin Bhagwagar (New Haven)

09:00  Symposium 5 – Queen’s Suite 1

New treatment strategies for targeting drug addictions – a translational perspective
Chairs: Mohammed Shoaib, Gavin McNally

09:00  Animal models of nicotine dependence based on associative learning to target cue reactivity
       Mohammed Shoaib (Newcastle)

09:30  Environmental determinants of addiction-related behaviours in rodents:
       Focus on environmental enrichment
       Marcello Solinas (Poitiers)

10:00  Refreshments in Hall H

10:30  The role of contexts in promoting and preventing relapse to drug seeking
       Gavan McNally (New South Wales)

11:00  The role of attention and the impact of substance cues in mediating goal-directed substance-seeking
       Abi Rose (Liverpool)
09:00  Symposium 6 – Queen’s Suite 2

Functional imaging markers for monitoring treatment: mechanisms and efficacy
Chairs: Mitul Mehta, Catherine Harmer

09:00  Functional MRI of the anxiogenic drug Yohimbine: Imaging the neural circuitry of stress and its pharmacological modulation
Allesandro Gozzi (Pisa)

09:30  Imaging the effects of glutamatergic modulation with ketamine: phMRI, fMRI and quantitative perfusion
Mitul Mehta (London)

10:00  Refreshments in Hall H

10:30  Linking brain modulation with measures of food intake and weight loss in the treatment of obesity
Pradeep Nathan (Cambridge)

11:00  Imaging hallmarks of treatment response in major depression
Catherine Harmer (Oxford)

11:45  2012 Post-Doctoral Symposium – Queen’s Suite 1

Neurodevelopmental models of psychiatric disease: back to the future

11:45  The relationship between structural, functional and effective connectivity in subjects of high genetic risk in schizophrenia
Maria Dauvermann (Edinburgh)

11:45  Examining the role of dopamine D2 and D3 receptors on behavioural changes in the social isolation reared rat – a neurodevelopmental model of symptoms of David Watson (Nottingham)

12:00  Animal model of autism induced by prenatal exposure to valproic acid: Novel implications
Tomasz Schneider (Oxford)

12:15  MAM E17 Model: The Lilly experience so far
Nadia Malik (Windlesham)

12:30  Cross-fostering in rodents: A model of psychiatric disease?
Stephen Hall (Newcastle)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>Lunch and Poster Preview in Hall D</td>
</tr>
<tr>
<td>12:45</td>
<td>Journal of Psychopharmacology - Editorial Board Meeting Meeting Room 1 (lunch provided)</td>
</tr>
<tr>
<td>13:45</td>
<td>Therapeutic Advances in Psychopharmacology - Editorial Board Meeting Meeting Room 1</td>
</tr>
<tr>
<td>14:00</td>
<td>Poster Session 2 in Hall D</td>
</tr>
<tr>
<td></td>
<td>Anxiety 2 / Affective Disorders 2 / Sleep / Cognition 2 / Neuropharmacology / Schizophrenia 2 / Feeding and Eating / Substances of Abuse 2 / Psychomotor Stimulants</td>
</tr>
<tr>
<td></td>
<td>Presenters should stand by their Poster between 14:00-15:00</td>
</tr>
</tbody>
</table>
TUESDAY GROUP A

ANXIETY 2

Guidelines, prescriptions and treatment restrictions in secondary care treatment of patients with generalized anxiety disorder: an international questionnaire survey

Bolognesi F, Allgulander C, Bandelow B, Pallanti S, Baldwin DS

Survey on discharge letters for patients with mixed anxiety and depression, and adjustment disorder in Bedford Crisis Resolution Team

Dissanayake LK, Gadalkarim W, Sule A, Ratnayake TB

Social anxiety is associated with a loss of positive self-referential bias in a probabilistic social learning task

Button KB, Lewis G, Munafò MR

This will also be presented orally on Tuesday afternoon

Decision-making in Obsessive-Compulsive Disorder: compulsivity and hoarding are associated with poorer performance

Kaser M, Hacioglu M, Yildirim EA, Saatcioglu O

Cannabidiol as a pharmacological adjunct to virtual reality exposure therapy in the treatment of Acrophobia

Fisher MJ, Muetzelfeldt L, Swapp D, Curran HV, Morgan CJA

TUESDAY GROUP B

AFFECTIVE DISORDERS 2

Captodiamine, a putative antidepressant, reverses anhedonia induced by chronic mild stress and exerts a specific trophic action in the hypothalamus of C57/Bl6 mice

Ring R, Regan CM

Investigating the mechanism underlying delayed versus rapid antidepressant action using a novel rodent model of affective state-induced memory bias

Stuart SA, Butler P, Nutt DJ, Robinson ESJ

A potentially novel index of maternal-infant bond: Bandwidths of B62DF1 mouse pup ultrasonic vocalisations are decreased by maternal chronic mild stress, effects which are blocked by maternal clomipramine treatment

Trist AJ, Aziz HA, Stevenson C, Pardon MC

Chronic and acute physical illness in the child: effect of exposure to maternal stress during pregnancy

Wertz JW, Kanani R, Flynn S, Plant D, Pariante CM, Pawlby S

Exposure to depression in utero predicts childhood medical problems

Plant DT, Pariante CM, Pawlby S
Working memory performance in postpartum psychosis
Pauls AM, Mehta MA, O’Daly OG, Pawlby S, Ciufolini S, Hazelgrove K, Veccio C, Williams SCR, Pariante CM, Dazzan P

When less is more: Investigating working memory in patients recovered from depression
Norbury R, Godlewksa B, Cowen PJ

MMRM or LOCF for assessing efficacy in MDD: results from a randomised placebo- and comparator-controlled study
Baldwin DS

Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: Post-hoc analysis findings from a European observational study
Lenox-Smith A, Quail D, Martinez J, Classi P

Early increase in a neuronal integrity marker with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate

The role of polyunsaturated fatty acids on Interferon-alpha induced clinical factors

Further evidence on the antidepressant efficacy of 3β-methoxy-pregnenolone (MAP4343) in experimental models: effects in tree shrews (Tupaia belangeri) exposed to chronic psychosocial stress
Parésys L, Hoffmann K, Bate S, Baulieu EE, Fuchs E, Bianchi M

Effects of SSRIs on bodyweight, hormones and hippocampal microtubular and synaptic proteins in female tree shrews (Tupaia belangeri): comparison with MAP4343 (3β-methoxy-pregnenolone)
Leandri J, Hoffmann K, Bate ST, Baulieu EE, Fuchs E, Bianchi M

Activation of serotonin receptors in human hippocampal progenitor cells affects gene expression of the glucocorticoid receptor and nerve growth factor inducible factor A
Musaelyan K, Anacker C, Zunszain PA, Pariante CM

MR- and GR-dependent molecular pathways differentially regulating human hippocampal neurogenesis
Anacker C, Cattaneo A, Musaelyan K, Zunszain PA, Thuret S, Price J, Pariante CM

Anti-inflammatory action of antidepressants in human hippocampal stem cells
Horowitz MA, Zunszain P, Anacker C, Musaelyan K, Pariante CM

INFLAME-BEAT: Understanding the role of inflammation in predicting depression in patients with heart disease
Nikkheslat N, Tylee A, Pariante CM, Carvalho LA
A 5-HT2A receptor polymorphism is associated with the development of serotonin syndrome following antidepressant treatment

Yevtushenko OO, Oros MM, Reynolds GP

Cognitive dysfunction and mood disorder: a systematic review

Rock PL, Roiser, JP, Riedel, WJ, Blackwell AD

The relationship between asthma and bipolar disorder. A nationwide pharmacoepidemiological study

Svendal G, Fasmer OB, Engeland A, Williams L, Berk M, Lund A

Attitudes of European psychiatrists regarding use of long-acting injections in bipolar disorder

Patel MX, Scott J, Tacchi M-J

---

**TUESDAY GROUP C**

**SLEEP**

Rhythmic day/night variation in histone acetylation in the hippocampus of c57BL/6 mice

Oyegbami O, Collins HM, Pardon MC, Heery DM, Moran PM

Locomotor activity measured over a 24h period using telemetry is substantially higher in NK1R-/- mice only during the dark phase

Dudley JA, Moyes AJ, Stanford SC, Hunt SP

The acute effects of a 5HTP supplement on daytime mood, performance and subjective night sleep

Alford CA, Davies S

Severity of insomnia, attentional control and thought intrusions in healthy volunteers

Baker LD, Lynn J, Wingfield M, Winmill L, Wickens R, Baldwin DS, Garner M

Neuropsychological and HPA-axis correlates of sleep in healthy subjects: implications or bipolar affective disorder


---

**TUESDAY GROUP D**

**COGNITION 2**

Behavioural evaluation of a rat model of ASD following gestational exposure to valproate


Is altered learning and memory in a prenatal valproate animal model of autistic spectrum disorder due to changes in neurogenesis?


An animal model for the fetal valproate syndrome - with relevance to autism

Bertelsen F, Möller A, Landau AM, Scheel-Kruger J
Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorders

Effects of selective nicotinic agonists in two cognitive domains and in two models of cognitive impairment in female rats: relevance for improving treatment of schizophrenia and Alzheimer’s disease
McLean SL, Idris NF, Marsh S, Zarroug SHO, Grayson, Harte MK, Neill JC

The effect of memantine on repetitive behaviours in the Tg2576 mouse model of Alzheimer’s disease
Middleton LJ, Good, MA
This will also be presented orally on Tuesday afternoon

Effect of an orexin-1 receptor antagonist on progressive-ratio schedule performance: evidence for an involvement of orexin-1 receptors in the regulation of incentive value
Olarte-Sánchez CM, Valencia-Torres L, Body S, Cassaday H, Bradshaw CM, Szabadi E

Early markers of cognitive enhancement: Developing an implicit measure of cognitive performance
Pringle A, Browning M, Parsons E, Cowen PJ, Harmer CJ
This will also be presented orally on Tuesday afternoon

The role of serotonin in decision-making as shown by PET

Scopolamine influences on brain activity during paired associates learning: A multivariate approach
Joules R, Marquand AF, Doyle OM, Mehta MA

A comparative study of the effects of neonatal exposure to clomipramine, amitriptyline and fluoxetine on behaviour in later life in an animal model

A new computer program under development for scoring and processing behavioural data
Kokras N, Theocharis F, Kafetzopoulos V, Papadopoulos-Daifoti Z, Dalla C, Baltas D

Phenotypic studies on conditional mutant mice with progressive loss of Drd1a cells in relation to Huntington’s disease
O’Leary C, Massalas J, Waddington JL, Drago J

Investigating the role of mGlu2 receptors in DOI-induced head-twitch responses using a Wistar rat strain lacking mGlu2 expression
Wood CM, Mitchell EA, Lodge D, Robinson ES
Neural inflammation and kynurenine pathway: Differential effects of omega-3 and omega-6 polyunsaturated fatty acids  

Profound suppression of noradrenaline, dopamine and 5-HT turnover in various regions of rat brain evoked by the α2-adrenoceptor agonist, clonidine  
**Heal DJ**, Sood P, Prow M, Rowley H

A single dose of fluoxetine modulates anger processing in young healthy volunteers  
**Capitão LP**, Murphy SE, Harmer CJ

---

**TUESDAY GROUP F**

**SCHIZOPHRENIA 2**

**Behavioural analysis of a C-terminal region DISC1 mutant mouse**  
**Dachtler J**, Rodgers RJ, Clapcote SJ

**Maternal immune activation induces executive dysfunction and changes in GABAergic interneurones in the prefrontal cortex**  
**Wallace J**, McQuade R, Marston HM, Gartside SE

**Altered cerebral metabolism and functional connectivity in a schizophrenia-related disease model: Impact of Poly IC and THC on the developing brain**  
**Stenson GM**, Brett R, Dawson N, Pratt JA

**Catechol-O-methyltransferase (COMT) inhibition and Δ9-tetrahydrocannabinol (THC) have interactive effects on dopamine levels in the nucleus accumbens**  
**Stumpenhorst K**, Kaenmaki M, Harrison PJ, Sharp T, Tunbridge EM  
*This will also be presented orally on Tuesday afternoon*

**Cannabis use and psychotic experiences in UK teenagers - A longitudinal study using ALSPAC**  
**Gage SH**, Hickman M, Heron J, Munafo MR, Zammit S

**Cognitive remediation training effects are not influenced by IQ in patients with schizophrenia**  
*This will also be presented orally on Tuesday afternoon*

**A naturalistic evaluation of the use of paliperidone palmitate at a South London NHS Foundation Trust: 6 month interim results on the first 120 patients**  
**Taylor DM**, Attard A

**Neural substrates mediating the cognitive-enhancing effects of nicotine: Implications for self-medication in schizophrenia**  
**Mitchelmore R LJ**, Hasan S, Rushforth S, Steckler T, Shoaib M

**Nicotine restores the ketamine-induced impairment of cognitive flexibility in rats**  
**Kohli S**, Shoaib M
Varenicline attenuates cigarette smoking abstinence-induced deficits in visuospatial working memory in schizophrenia
Wing VC, Wass CE, George TP

Nicotine is associated with improved cognitive performance but worse metabolic profile: Preliminary findings from a cohort of first episode psychosis patients

TUESDAY GROUP G
FEEDING AND EATING

Effects of the mu opioid receptor antagonist GSK1521498 on hedonic and consummatory behaviour: A proof of mechanism study in binge eating obese subjects

Effect of meta-chlorophenylpiperazine (mCPP) on emotional processing and mood in healthy volunteers
Thomas JM, Tomlinson J, Hassan-Smith Z, Dourish CT, Higgs S

Disruptive effects of bupropion on feeding behaviour and the behavioural satiety sequence in rats
Rodgers RJ, Wright F

TUESDAY GROUP H
SUBSTANCES OF ABUSE 2

The role of the NMDA receptor and B-adrenoreceptor in reward memory reconsolidation: A meta-analysis
Das RK, Freeman TP, Kamboj S

Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use
Freeman TP, Morgan CJA, Pepper F, Howes OD, Stone JM, Curran HV

The effect of long-term ketamine use on cognition and psychopathology
Pepper FS, Stone JM, Howes OD, Morgan CJA

Extracts of Khat (Catha edulis) increase dopamine release and bind to D1 and D2 dopamine receptors in rat striatum
Ismail M, Houghton P, Rose S

Intravenously administered psilocybin in the fMRI environment - A phenomenological analysis
Turton S, Carhart-Harris RL, Feilding A, Nutt DJ
Effect of repeated mephedrone on core body temperature and locomotor activity in the rat

Shortall SE, Green AR, King MV, Fone KCF

The role of the 5-HT1 and 5-HT2 receptor in MDMA-induced effects on memory and mood

van Wel JHP, Kuypers KPC, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG

Co-operation is positively influenced by acute MDMA

Ferguson B, Stewart L, Fenton R, Jones L, Swaboda N, Roberts RE, Morgan CJA, Curran HV

Environmental enrichment can accentuate conditioned reward induced by representative cocaine doses in mice

Geuzaine A, Tirelli E

Investigating the properties of obsessive compulsive smoking in frequent smokers; the role of implicit attentional bias and explicit valence

Hindocha C, Freeman TP, Curran HV

Effects of plain tobacco packaging on visual attention to health warnings in adolescent smokers and non-smokers

Maynard OM, Munafò MR, Leonards U

Effects of 7.5% carbon dioxide challenge on physiological and subjective stress responses in daily cigarette smokers and non-smokers

Anderson MH, Attwood AS, Munafò MR

The effect of extinction on Pavlovian to instrumental transfer in smokers

Retzler CA, Hogarth L

Self-control in former smokers that have successfully maintained long term abstinence

Butler K, Rusted J, Gard P, Jackson A

Effects of smoking abstinence on attentional bias for emotional cues


TUESDAY GROUP I

PSYCHOMOTOR STIMULANTS

Methylphenidate significantly reduces lapses of attention during on-road highway driving and improves vehicle control (SDLP)

Cheung CW, van Seyen M, Olivier B, Roth T, Verster JC

Profiles of lisdexamfetamine, methylphenidate and modafinil in rats trained to discriminate d-amfetamine from saline

Heal DJ, Gosden J, Slater N, Hackett D

A microdialysis and behavioural comparison of lisdexamfetamine methylphenidate and modafinil in freely-moving rats

Heal DJ, Rowley H, Kulkarni R, Hackett D
15:15-16:15 Short Oral Presentations in Hall D, Queen’s Suite 1, Queen’s Suite 2

15:15 Short Oral Presentations 1 in Hall D

**New ways to model anxiety**
Chaired by Marcus Munafo

15:15 **Performance in an instrumental successive negative contrast task by Wistar rats with an anxiety-like phenotype**
Emma Mitchell
(Marston HM, Nutt DJ, Lodge D, Robinson ESJ)

15:30 **Social anxiety is associated with a loss of positive self-referential bias in a probabilistic social learning task**
Kate Button
(Lewis G, Munafò MR)

15:45 **Using 7.5% CO2 challenge to evaluate novel psychological treatments for anxiety**
Lucy Morris

16:00 **Probiotics and the brain: Effects on anxiety and reversal learning**
Caroline O’Hagan
(Lilburn A, Good MA)

15:15 Short Oral Presentations 2 in Queen’s Suite 1

**Cognitive enhancement: From aspiration to realisation**
Chaired by Liz Tunbridge

15:15 **The effect of memantine on repetitive behaviours in the TG2576 mouse model of Alzheimer’s Disease**
Laura Middleton
(Good, M)

15:30 **Robust and reproducible recognition memory deficit in rats induced by sub chronic PCP: Validation with antipsychotics and cognition enhancers**
Theresa Ballard
(Haman M)

15:45 **Early markers of cognitive enhancement: Developing an implicit measure of cognitive performance**
Abbie Pringle
(Browning M, Parsons E, Cowen PJ, Harmer CJ)

16:00 **Cognitive remediation training effects are not influenced by IQ in patients with schizophrenia**
Amir Inamdar
15:15  Short Oral Presentations 3 in Queen’s Suite 2

Cannabinoids: Toxic effects and treatment applications
Chaired by Mohammed Shoaib

15:15  Catechol-o-methyltransferase (COMT) inhibition and Δ-9-tetrahydrocannabinol (THC) have interactive effects on dopamine levels in the nucleus accumbens
Katharina Stumpenhorst
(Kaenmaki M, Harrison PJ, Sharp T, Tunbridge EM)

15:30  In vivo brain dopamine synthesis capacity and cannabis related psychotic symptoms: An [18F]-DOPA positron emission tomography study in cannabis users
Michael Bloomfield
(Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD)

15:45  Frontal brain volumes in early adolescence differentially predict the development of alcohol-related problems and cannabis use at age 16: A 4-year longitudinal and prospective cohort study
Dan Lubman
(Cheetham A, Whittle S, Simmons J, Yucel M, Allen NB)

16:00  Executive function deficits in abstinent cannabis users: The effect of the age of onset
James Reynolds
(McHale S, Barker L, Reidy L, Dalton C)

16:15  BAP Psychopharmacology Awards – Oral Presentations in Hall D
Chaired by Barbara Sahakian

16:15  Karen Ersche (University of Cambridge)
Lifting the veil on addiction vulnerability

16:30  Marcus Munafo (University of Bristol)
Power, precision and phenotype in genetic association studies

16:45  Cynthia Fu (Institute of Psychiatry, London)
Developing neuroimaging-based biomarkers for diagnosis and prognosis in depression

19:00  Drinks Reception in the Lounge at the Majestic Hotel
For those attending the Conference Dinner

19:30  Conference Dinner at the Majestic Hotel
Conference Dinner

Home made ham hock and grain mustard terrine
With mixed leaves and Majestic piccalilli

Woodland mushroom and Yorkshire blue cheese tartlet (v)
With rocket salad and a honey mustard dressing

---

Roasted duck breast
With potato rosti, fine green beans, ribbons of carrot and a black cherry sauce

Asparagus and pea risotto (v)
Finished with a pesto dressing topped with fresh parmesan

---

Vanilla panna cotta
With a mixed berry compote and brandy snap biscuit

---

Tea, Coffee & chocolates

Dinner will be followed by the presentation of the 2012 BAP Awards
The evening will end with entertainment in the Ballroom from
“Take 3 at Night” and a Disco
**WEDNESDAY 25 JULY**

09:00       BAP desk opens in the Foyer of the Queen’s Suite

09:30-12:00 Symposia 7, 8 and 9 in Hall D, Queen’s Suite 1 and Queen’s Suite 2

09:30       Symposium 7 in Hall D

**Schizophrenia treatment: what’s wrong with it and what might work better**

Chairs: Barbara Sahakian, Oliver Howes

09:30       Animal models of limbic cortical dysfunction in schizophrenia: Implications for novel treatments
             Holly Moore (New York)

10:00       The effects of cannabis on the brain: in vivo studies of the dopaminergic and cannabinoid systems and the link to psychotic and affective symptoms
             Oliver Howes (London)

10:30       Refreshments in Hall H

11:00       Cognitive enhancement in schizophrenia
             Barbara Sahakian (Cambridge)

11:30       Genetic data implicate specific abnormalities of synaptic function in the pathogenesis of schizophrenia
             Michael Owen (Cardiff)

09:30       Symposium 8 – Queen’s Suite 1

**Epigenetics and psychiatry - current understanding and therapeutic potential**

Chairs: Jeremy Hall, Lawrence Wilkinson

09:30       Epigenetics and psychiatric disorders
             Jeremy Hall (Edinburgh)

10:00       Behavioural epigenetics; Exciting but uncertain prospects
             Lawrence Wilkinson (Cardiff)

10:30       Refreshments in Hall H

11:00       Epigenetics of the impact of early trauma on behaviour across generations
             Johannes Bohacek (Zurich)

11:30       The epigenetics of complex psychiatric disorders – novel treatment targets?
             Jonathan Mill (London)
09:30  Symposium 9 – Queen’s Suite 2

Rethinking the compulsive aspects of addiction: from bench to bedside
Chair: Sam Chamberlain

09:30  “Just can’t stop myself”. OCD versus addiction: clinical aspects  S33
Naomi Fineberg (Welwyn Garden City)

10:00  Mapping the overlap. Cognitive and imaging endophenotypes of OCD and addiction  S34
Sam Chamberlain (Cambridge)

10:30  Refreshments in Hall H

11:00  Novel pharmacological treatments for pathological gambling and related addictive disorders  S35
Jon Grant (Minnesota)

11:30  Zebrafish models of locomotor activity and impulsivity  S36
Klaus-Peter Lesch (Wuerzburg)

12:00  End of 2012 Summer Meeting
Confirmed Symposia for BAP 2013 Summer Meeting

Sunday 28 – Wednesday July, Harrogate

Monday 29 July
1. The neurobiology of social behaviour: pharmacological manipulation and recent advances in therapy
2. Brain-Derived Neurotrophic Factor (BDNF) and Synaptic Plasticity as a drug target for Cognitive Dysfunction in CNS Disorders
3. Experimental Medicine approaches in developing new treatments for anxiety disorders

Tuesday 30 July
4. Imaging dopamine in the living brain
5. Computational Psychopharmacology
6. Alzheimer’s disease early detection and early effective treatment

Wednesday 31 July
7. Can psychological constructs make good drug targets? The example of salience dysregulation in schizophrenia
8. Novel innovation in monitoring symptoms and treatments for schizophrenia and bipolar disorder
9. The impact of inflammatory challenges on mental function

Helen Mayberg of Emory University will present the 2013 Guest Lecture on Monday 29 July
The BAP was founded in 1974, with the general intention of bringing together those from clinical and experimental disciplines as well as members of the pharmaceutical industry involved in the study of psychopharmacology. To this end the Association arranges scientific meetings, fosters research and teaching, encourages publication of results of research and provides guidance and information to the public on matters relevant to psychopharmacology, where appropriate.

The BAP organises scientific meetings and symposia during the course of the year, covering all aspects of psychopharmacology from basic research to pharmaceutical development and clinical application. The Association has produced a range of consensus statements on the treatment of clinical disorders as well as on the investigation of psychopharmaceutical compounds.

BAP is committed to providing high-quality education for scientists and organises a number of educational and training events.

The BAP is one of the largest national psychopharmacology associations in the world.

Membership of the Association is open to any qualified worker in a discipline relevant to psychopharmacology. Existing members include pharmacologists, psychiatrists, psychologists, neurobiologists and pharmacists.

**Full Membership.** Applicants are eligible for Full Membership if they can demonstrate involvement in areas relevant to psychopharmacology by, for example, qualifications, publications or research activity.

**Training Membership.** This category is designed to support young scientists with a limited income, such as a research studentship, and will normally be awarded only to those registered for a degree. BAP supports Training Members attending BAP meetings to gain experience in presenting their work. Preclinical training membership is limited to a 10-year maximum period (from the point of registration as a preclinical trainee member) or until the trainee attains a tenured post in academia or a full-time position in a pharmaceutical company.

Application for Membership must include the name and address of a FULL member of BAP willing to sponsor the application OR be accompanied by a full CV. Full members receive the Journal of Psychopharmacology free of charge.

Online applications are welcomed: [http://bap.org.uk/association/appform.html](http://bap.org.uk/association/appform.html)

**CURRENT MEMBERSHIP RATE**

<table>
<thead>
<tr>
<th>Membership Type</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Membership</td>
<td>£80.00 p.a.</td>
</tr>
<tr>
<td>Training Membership</td>
<td>£20.00 p.a.</td>
</tr>
</tbody>
</table>

**BAP Consensus Guideline Documents** (all available at [www.bap.org.uk](http://www.bap.org.uk)):

- Evidence-based guidelines for treating Bipolar Disorder (published 2009)
- Evidence-based guidelines for treating depressive disorders with antidepressants (published 2008)
- Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the BAP (published 2010)
- Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults (published 2006)
- Evidence-based guidelines for the pharmacological treatment of anxiety disorders (published 2005)
- BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP (published 2012)
- BAP consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders (published 2010)
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the BAP (published 2011)
APPLICATION FOR MEMBERSHIP OF THE BAP

This application must include either the name of a Full Member of BAP willing to support the applicant, or a copy of the applicant’s curriculum vitae

TITLE ................... FIRST NAME ............................. LAST NAME.................................

DATE OF BIRTH .....................................................................................

APPLYING FOR: FULL MEMBERSHIP @ £80 p.a. 
TRAINING MEMBERSHIP* @ £20 p.a. 
*This requires a supporting statement from your BAP sponsor

CURRENT WORK ADDRESS: .................................................................
........................................................................................................................................

TEL: .................................................................... FAX:........................................................

EMAIL: ................................................................................................................................

Year of PhD award (if applicable) ........................................

DEGREES (including dates and awarding body)
...........................................................................................................................................
...........................................................................................................................................

PRESENT POST: .................................................................................................

PLEASE TICK THAT WHICH BEST DESCRIBES YOUR STATUS/INTEREST:

○ Clinical ○ Pre-clinical ○ Industrial ○ Other

ARE YOU RESEARCH ACTIVE? ○ Yes ○ No

SPECIFIC INTEREST IN PSYCHOPHARMACOLOGY
(i.e. psychiatric, psychological, experimental, pharmaceutical)
...........................................................................................................................................

NAME OF BAP FULL MEMBER WILLING TO SPONSOR THIS APPLICATION:
...........................................................................................................................................

SIGNATURE OF APPLICANT: ................................................. DATE: ................................

*SUPPORTING STATEMENT FOR SPONSORS OF TRAINING MEMBERSHIP APPLICANTS
I certify that the person named above qualifies for BAP Training Membership on the grounds of
(a) being a full or part-time student with a limited income OR
(b) other reason (please specify)

SIGNATURE OF SPONSOR: ............................................. NAME (print): .................................

Please send completed Application Form to the BAP Office
36 Cambridge Place, Hills Road, Cambridge CB2 1NS
Tel: 44 (0) 1223 358 395 Fax: 44 (0) 1223 321 268
Email: lynne@bap.org.uk (Lynne Harmer, Assistant to the Executive Officer)

DO NOT SEND PAYMENT WITH THIS FORM